Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 13/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5232757 | 0.85 | CYP1A2 (0.41) | GRM5CYP1A2CYP3A4CACNA1CSCN5A | |
| SCHEMBL23389973 | 0.84 | GRM5 (0.49) | GRM5CYP1A2CYP3A4FFAR1NPC1 | |
| SCHEMBL3272875 | 0.78 | GRM5 (0.53) | GRM5CYP1A2CYP3A4FFAR1NPC1 | |
| SCHEMBL6578921 | 0.78 | GRM5 (0.58) | GRM5CYP1A2CYP3A4FFAR1NPC1 | |
| SCHEMBL30898832 | 0.78 | GRM5 (0.52) | GRM5CYP1A2FFAR1SMN1; SMN2KDM4E | |
| SCHEMBL852762 | 0.78 | GRM5 (0.52) | GRM5CYP1A2FFAR1SMN1; SMN2KDM4E | |
| SCHEMBL24737357 | 0.74 | SMN1; SMN2 (0.41) | GRM5CYP1A2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4710798 | 0.74 | GRM5 (0.54) | GRM5CYP1A2CYP3A4NPC1RAB9A | |
| SCHEMBL15841075 | 0.72 | HTT (0.44) | CYP1A2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL13162467 | 0.72 | CYP1A2 (0.64) | GRM5CYP1A2CYP3A4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365066-B2 | Pyrazolopyridine derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365066-B2 | Pyrazolopyridine derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1543001-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1543001-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1397364-B1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | LILLY CO ELI (US) | 2007-07-25 | — | — | EP | disclosed |
| US-7087626-B2 | Pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| US-20050222197-A1 | Novel pyrazolopyridine derivatives as pharmaceutical agents | BEIGHT DOUGLAS W | 2005-10-06 | — | — | US | disclosed |
| EP-1543001-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY | 2004-06-03 | — | — | US | disclosed |
| WO-2004026871-A1 | NOVEL PYRAZOLOPYRIDINE DERIVATVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
| EP-1397364-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002094833-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222197-A1 | Novel pyrazolopyridine derivatives as pharmaceutical agents | TGFB2, TGFB1, TGFBR1 | GRM5 2325/4885CYP1A2 4047/4885CYP3A4 2285/4885 |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | TGFBR1, SMAD3, TGFBR2 | GRM5 944/4885CYP1A2 3968/4885CYP3A4 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.